In the latest committee election held by the International Association for the Study of Lung Cancer (IASLC), Professor Wu Fang from our hospital has been appointed as a member of the Staging and Prognostic Factors Group (SPFG). This appointment recognizes her significant contributions to lung cancer staging and treatment. As part of her new role, Professor Wu will contribute to the revision and updating of the 10th Edition of the International Lung Cancer TNM Staging System. This prestigious election not only affirms Professor Wu Fang’s expertise in precise lung cancer prevention and treatment but also underscores the growing international influence of our hospital in the field of lung cancer research.
Founded in 1974, the IASLC is the world’s first and only professional academic association dedicated to the study of lung cancer and thoracic tumors. With over 10,000 members from more than 100 countries and regions, the IASLC is a global leader in advancing research, diagnosis, and treatment of lung cancer and thoracic malignancies. The SPFG plays a pivotal role in the revision and improvement of the global lung cancer staging system, with its work profoundly shaping the future of lung cancer diagnosis, treatment, and research.